创模生物科技(北京)有限公司

CN / En

NEWS

Introduction to the iHuPDX model of InnoModels Biotechnology

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-08-16 16:12
  • Views:

(Summary description)The iHuPDX model of InnoModels Biotechnology is a xenotransplantation technology based on individual patient's tumor cells, aiming to establish a more realistic and individualized cancer model. 

Introduction to the iHuPDX model of InnoModels Biotechnology

(Summary description)The iHuPDX model of InnoModels Biotechnology is a xenotransplantation technology based on individual patient's tumor cells, aiming to establish a more realistic and individualized cancer model. 

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-08-16 16:12
  • Views:
Information

The iHuPDX model of InnoModels Biotechnology is a xenotransplantation technology based on individual patient's tumor cells, aiming to establish a more realistic and individualized cancer model. 
The iHuPDX technology provides a tumor model that more closely matches the patient's actual condition by collecting cancer tissue samples from the patient and transplanting them into an animal, such as a mouse, to form an individualized transplanted tumor. Key advantages of this technology include.
Individualized Disease Models: iHuPDX technology establishes highly individualized disease models based on individual patient's tumor cells, which helps to provide a more comprehensive understanding of the patient's tumor characteristics, and providing important support for precision medicine. 

 


Drug response prediction: Due to the highly individualized nature of the model, iHuPDX technology can be used to test the response of different drugs to a specific patient's tumor, providing a powerful tool for the development of personalized treatment plans, which is expected to improve the success rate of treatment. for the development of personalized treatment plans, which is expected to improve the success rate of treatment. 
New perspectives in cancer research: iHuPDX technology enables researchers to probe more deeply into the differences in tumor heterogeneity among different patients, helping to reveal the diversity of cancers and providing important information for the development of individualized treatment strategies. strategy development. 
Founded by scientists from Novo Nordisk China R&D Center, SinoMediGuanco, and the Institute of Immunology at Shanghai Jiao Tong University, InnoModels Biotechnology (Beijing) Co., Ltd. is confident in the future of iHuPDX technology. With the deepening of biomedical research and continuous technological innovation, iHuPDX is expected to play a more important role in the field of personalized medicine. In the future, we can expect to see more research results and application scenarios related to iHuPDX technology.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司